LBA71Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)

ConclusionsThe PEMDAC study has demonstrated that combined HDAC- and PD-1-inhibition can result in clinical efficacy in metastatic uveal melanoma with manageable toxicities. The obtained data warrant further investigation to address clinical and immunological characteristics of patients achieving clinical benefit.Clinical trial identificationNCT02697630 (Registered 3 March 2016). EudraCT: 2016-002114-50.Legal entity responsible for the studySahlgrenska University Hospital, V ästra Götaland Region.FundingSyndax Pharmaceuticals and Merck& Co. Inc.DisclosureR. Olofsson Bagge: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). G. Ullenhag: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). I. Ljuslinder: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). M. Levin: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). U. Stierner: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). L. Ny: Advisory / Consultancy: Merck& Co. Inc. (MSD Sweden). All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research